SCHEMBL503143

SCHEMBL503143

COc1cc(C(=O)CBr)cc(OC)c1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
GAA P10253 1/20 0.54
GSK3B P49841 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
TUBB4A P04350 2/20 0.50
TUBB P07437 2/20 0.50
TUBA3C P0DPH7 2/20 0.50
TUBA1B P68363 2/20 0.50
TUBA4A P68366 2/20 0.50
TUBB4B P68371 2/20 0.50
TUBB3 Q13509 2/20 0.50
TUBB2A Q13885 2/20 0.50
TUBB8 Q3ZCM7 2/20 0.50
TUBA3E Q6PEY2 2/20 0.50
TUBA1A Q71U36 2/20 0.50
TUBA1C Q9BQE3 2/20 0.50
TUBB6 Q9BUF5 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205400 0.90 TSHR (0.66) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL1188279 0.88 ALDH1A1 (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL1929760 0.86 TUBB4A (0.47) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL2390640 0.85 GSK3B (0.52) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL11162299 0.85 PKM (0.60) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL12418371 0.85 MEN1 (0.56) MEN1KMT2AALDH1A1KDM4EGSK3B
SCHEMBL7369355 0.84 HPGD (0.46) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL1447632 0.84 TPMT (0.51) MEN1KMT2AALDH1A1KDM4EGSK3B
SCHEMBL7046987 0.84 ALDH1A1 (0.72) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL9828028 0.84 MEN1 (0.62) MEN1KMT2AALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108341831-B 7H- [1,2,4] triazolo [3,4-b ] [1,3,4] thiadiazine-phenylhydrazone type compounds 贵州医科大学 2020-10-09 CN claimed
US-12421257-B2 Compositions and methods for inhibiting group II intron RNA YALE UNIVERSITY (US) 2025-09-23 US disclosed
US-20240018169-A1 COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA UNIV YALE (US) 2024-01-18 US disclosed
US-11739104-B2 Compositions and methods for inhibiting group II intron RNA YALE UNIVERSITY (US) 2023-08-29 US disclosed
EP-4219486-A1 NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE Temple University of the Commonwealth System of Higher Education (US) 2023-08-02 EP disclosed
EP-4219486-A1 NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE Temple University of the Commonwealth System of Higher Education (US) 2023-08-02 EP disclosed
EP-3571196-B1 NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE UNIV TEMPLE (US) 2023-01-04 EP disclosed
EP-3571196-B1 NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE UNIV TEMPLE (US) 2023-01-04 EP disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
US-4469695-A 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives AYERST, MCKENNA & HARRISON, INC. (CA) 1984-09-04 US disclosed
US-4451650-A ANTITUMOR AGENTS SOUTHERN RESEARCH INSTITUTE (US) 1984-05-29 US disclosed
EP-0107130-A1 Pyrido(4,3-b)(1,4) oxazines and pyrido(4,3-b) (1,4)thiazines Southern Research Institute (US) 1984-05-02 EP disclosed
US-4446141-A Hypotensive piperidine derivatives KYOWA HAKKO KOGYO CO. (JP) 1984-05-01 US disclosed
EP-0018417-B1 NOVEL PIPERIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KYOWA HAKKO KOGYO CO., LTD (JP) 1982-06-30 EP disclosed
EP-0034894-A2 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives, processes for their preparation, intermediates used in the processes and the preparation thereof and pharmaceutical compositions containing the derivatives AYERST, MCKENNA AND HARRISON INC. (CA) 1981-09-02 EP disclosed
EP-0018417-A1 Novel piperidine derivatives and pharmaceutical compositions containing them KYOWA HAKKO KOGYO CO., LTD (JP) 1980-11-12 EP disclosed
US-4190594-A ABSORBERS OF ULTRAVIOLET RADIATION JOHNSON & JOHNSON (US) 1980-02-26 US disclosed
US-4108880-A ULTRAVIOLET ABSORBERS JOHNSON & JOHNSON (US) 1978-08-22 US disclosed
US-3997557-A ANTIARRHYTHMIA, CNS DEPRESSANT, ANTIINFLAMMATORY, HYPOTENSIVE AMERICAN HOECHST CORPORATION (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421257-B2 Compositions and methods for inhibiting group II intron RNA NSUN2, RBM22, RNGTT MEN1 3207/4885KMT2A 2712/4885ALDH1A1 2984/4885
US-11739104-B2 Compositions and methods for inhibiting group II intron RNA NSUN2, RBM22, RNGTT MEN1 3207/4885KMT2A 2712/4885ALDH1A1 2984/4885
US-20240018169-A1 COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA NSUN2, RBM22, RNGTT MEN1 3207/4885KMT2A 2712/4885ALDH1A1 2984/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.